Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer

BACKGROUND: Cyclin‐dependent kinase (CDK) 4 and 6 inhibitors have significantly improved survival in patients with hormone receptor–positive metastatic breast cancer. There are few data regarding the epidemiology of cardiovascular adverse events (CVAEs) with these therapies. METHODS AND RESULTS: Usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Fradley, Michael G., Nguyen, Nam H. K., Madnick, David, Chen, Yiqing, DeMichele, Angela, Makhlin, Igor, Dent, Susan, Lefebvre, Benedicte, Carver, Joseph, Upshaw, Jenica N., DeRemer, David, Ky, Bonnie, Guha, Avirup, Gong, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356048/
https://www.ncbi.nlm.nih.gov/pubmed/37301767
http://dx.doi.org/10.1161/JAHA.123.029361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356048/
https://www.ncbi.nlm.nih.gov/pubmed/37301767
http://dx.doi.org/10.1161/JAHA.123.029361

Ejemplares similares